Objectif
While prevention of most female specific cancers (ovarian, breast, endometrial) has not progressed substantially in recent years, significant progress has been made with cervical cancer due to accessibility of the cell of origin (cervical smear) and availability of a test for the causal agent (human papilloma virus); together these enable identification of high risk individuals and interventions to prevent infection or halt progression to invasive cancer.
Our consortium has developed an exciting opportunity to utilise clinically abundant cervical cells in tandem with a multi-omics enabled (genome, epigenome, metagenome) analysis pipeline to understand an individual’s risk of developing a female specific cancer and to direct a personalised screening and prevention strategy. Cervical cells – currently collected within cervical cancer screening – provide an ideal window into other female specific cancers because they are (i) an excellent non-invasive source of high quality DNA, (ii) provide a readout for environmental exposure, (iii) are part of the Müllerian tract and (iv) are hormone sensitive, recording (via the epigenome) various hormonal conditions over a lifetime that trigger cancer development. The FORECEE project is aligned with the novel concept of “P4 Medicine” (predictive, preventive, personalized, and participatory): it aims to translate the risk prediction tool’s output into personalised recommendations for screening and prevention of female cancers.
Our consortium comprises a multi-disciplinary team of experts in clinical oncology, risk-benefit communication, omics technologies, decision analysis, health economics and public health. We will examine the effectiveness of the proposed cervical cell omics analysis method and investigate the legal, social, ethical and behavioural issues related to implementation of the risk prediction tool, through direct interaction with stakeholder groups, to ensure its rapid translation into clinical practice across Europe.
Champ scientifique
- medical and health scienceshealth sciencespublic health
- medical and health sciencesbasic medicinephysiologycytology
- medical and health sciencesclinical medicineoncologycervical cancer
- social scienceseconomics and businesseconomicshealth economics
- medical and health scienceshealth sciencesinfectious diseasesDNA viruses
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
WC1E 6BT London
Royaume-Uni
Voir sur la carte
Participants (14)
17177 Stockholm
Voir sur la carte
116 36 Praha 1
Voir sur la carte
5021 Bergen
Voir sur la carte
20121 Milano
Voir sur la carte
SO16 6YD Southampton
Voir sur la carte
Entité juridique autre qu’un sous-traitant qui est affiliée ou juridiquement liée à un participant. L’entité réalise des travaux dans les conditions prévues par la convention de subvention, fournit des biens ou des services pour l’action, mais n’a pas signé la convention de subvention. Le tiers respecte les règles applicables au participant qui lui est lié dans le cadre de la convention de subvention en ce qui concerne l’éligibilité des coûts et le contrôle des dépenses.
SO17 1BJ Southampton
Voir sur la carte
80539 Muenchen
Voir sur la carte
WC1E 7HT London
Voir sur la carte
Participation terminée
CB2 1TN Cambridge
Voir sur la carte
3015 GD Rotterdam
Voir sur la carte
6020 INNSBRUCK
Voir sur la carte
80539 Munchen
Voir sur la carte
Participation terminée
LN1 1XW Lincoln
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
78467 Konstanz
Voir sur la carte